The UK is cementing its position as a global leader in cell and gene therapy, according to new data

A report by the UK BioIndustry Association (BIA), in collaboration with Citeline, reveals a robust sector with significant investment, the highest number of clinical trials in Europe, and NHS patients benefitting from life-changing treatments.

The study shows that the UK is:

An investment hotspot: UK companies secured 55% of Europe’s cell and gene therapy VC funding in 2023, showcasing the strength of the UK ecosystem.

A clinical trial leader: With 84 drugs in clinical development, the UK surpasses all other European countries, offering patients early access to these innovative therapies.

Turning promise into reality: 23 cell and gene therapies are already approved for patient use in the UK, demonstrating the sector’s ability to deliver tangible benefits.

A major driver of innovation.

Steve Bates, BIA CEO, said: “The UK’s cell and gene therapy sector isn’t just about research. It’s about real-world impact.

“In 2022, we saw companies like Autolus and Orchard, born from the ingenuity of UK institutions like UCL, translate their pioneering work into tangible results.

“Orchard’s gene therapy reaching newborns with MLD exemplifies the extraordinary potential of this field. These are not just advancements – they are stories of lives saved, transformed, and empowered.

“The UK’s leadership in cell and gene therapy is a testament to our unwavering dedication to patient-centric advancements that rewrite the boundaries of healthcare.”

The report also acknowledges challenges facing the sector, including around manufacturing, talent, and patient access. BIA emphasises its commitment to collaboration with stakeholders to address these hurdles and ensure the UK remains a global leader in this field.

“We’re working closely with the government, NHS, and industry to overcome these challenges and ensure long-term success,” said Bates. “Together, we can unlock the full potential of cell and gene therapies to improve the lives of patients in the UK and around the world.”